Cancer Immunotherapies

• Cancer is a group of diseases that are characterized by abnormal cell growth. It involves a multi-step process because a single mutation is almost certainly not sufficient to become a malignant cell.
• Some cellular processes are deregulated that will allow the cells to proliferate uncontrollably while avoiding apoptosis. Initially, key cell growth, pro-apoptotic and proliferative signaling pathways are deregulated in most of the cancers. These signaling pathways lead to cell survival, continued proliferation and the avoidance of programmed cell death.
• The diseases are caused by the accumulation of genetic mutations that provide selective advantages allowing cells to evolve and accumulate virtually in all sites and tissues of the human body.
• Immunotherapy of cancer is a type of cancer treatment that stimulates the human bodies natural immune system to fight against the malignant cells.
• This therapy is introduced to the cancer patients to stop the spread of cancer, to decline the growth of cancer cells and to boosts the natural immunity for destroying the cancer cells.
• The introduction of advanced treatment options in cancer immunotherapy that are more effective and efficient are resulting in rising R&D. The shift of therapies from traditional chemotherapies to immunotherapies is prompting the overall market.
• However, the demand in the market is augmented by more significant factors. For example, the launch of more effective bioinformatics tools and rise in the requirement of cancer monoclonal antibodies that offers improved drug development options will help with more demand for cancer immunotherapy.
• Further, the surge in providing immunotherapy therapeutics compared to conventional ones and a high number of cancer incidences could increase market growth in the coming years.
• Cancer immunotherapies are targeted for treating several types of cancer including Lung cancer, Breast cancer, Colorectal cancer, Melanoma cancer, Prostate cancer, Head & Neck cancer, melanoma, NSCLC, and ovarian cancer. Cancer immunotherapies use to treat these cancers by using the products including antibody drug conjugates (ADCs), cytokines, bispecific monoclonal antibodies, interferons, PD-1/PD-L1 inhibitors, chimeric antigen receptor (CAR) T-Cell Therapy, dendritic cells, IDO inhibitors and adopted cell therapy (ACT).
• The market size for cancer immunotherapies is known to grow at an increasing rate over the forecast period. Overall, there are 2,037 products found to be in active development in the pipeline of cancer immunotherapy.
• This makes a significant portion of the entire oncology pipeline and adds a strong interest in product development in this class of therapy.
• This is because of the growing clinical rationale besides developing such therapies, and the interest of drug developers to invest in developing novel therapeutics, which will offer appropriate product differentiation from competitors of the market. Anyway, the cancer immunotherapy pipeline is found to be clearly strong; a notable proportion is made up by early-stage products, those from the discovery stage to phase I.
• This indicates the difficulty that is associated with progressing cancer immunotherapies from the preclinical laboratory to clinical application studies in humans.
• Immunotherapies found to have fewer side effects and thus hold high efficacy to treat various cancers. Cancer immunotherapies have made nearly 50% of the cancer drugs in the market. Development of targeted and combination therapies was trending now in the market for treating cancers.
• As the patent expiry of top-selling drugs in the market is taking place, thus it places a challenge for the development of novel drug therapeutics in cancer patients.
• The interest in cancer immunotherapy development has been driven by an increase in demand for cancer monoclonal antibodies and by the increased understanding of the immune system that acts as a hallmark of cancer pathophysiology, importantly immune evasion of developing cancer cells.